Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition intensifies

Novo Nordisk announced a major restructuring, cutting 9,000 jobs to reignite growth and counter intense competition from Eli Lilly and compounded drugs, following a rapid hiring spree and slowing momentum in its obesity and diabetes franchises. This move, projected to save 8 billion DKK annually but incurring 9 billion DKK in one-off costs, resulted in the company's third profit warning this year and a reduced 2025 operating profit growth forecast to 4-10%. The significant layoffs, marking new CEO Mike Doustdar's first major strategic shift, aim to simplify operations and redirect resources, coming as the stock has fallen nearly 46% year-to-date amid concerns over market misjudgment and organizational complexity.

Analysis

Novo Nordisk is undertaking a significant corporate restructuring, cutting 9,000 jobs to generate 8 billion Danish crowns ($1.25 billion) in annual savings. This defensive maneuver, the first major strategic shift under new CEO Mike Doustdar, is a direct response to slowing momentum in its core obesity and diabetes franchises and intense competition from Eli Lilly's Zepbound, which has surpassed Wegovy in U.S. weekly prescriptions. The overhaul has prompted the company's third profit warning this year, driven by a 9 billion crown one-off cost, and a sharp reduction in its 2025 operating profit growth forecast to 4%-10% from an initial 19%-27%. The market has severely punished the company for this slowdown, with its stock declining nearly 46% year-to-date and its market capitalization falling to $181 billion from a peak of approximately $650 billion. While the company aims to reinvest savings into its GLP-1 pipeline and boost manufacturing, some investors express concern that the cost-cutting is insufficient and that the firm misjudged the consumer-driven nature of the obesity market, leading to excessive organizational complexity during its recent hiring spree.

Key Decisions for Investors

• Investors should monitor the execution of the restructuring for evidence that the projected 8 billion DKK in annual savings can be achieved and effectively redeployed into the pipeline and manufacturing to defend market share.
• The competitive landscape is now the central risk factor; tracking weekly U.S. prescription data for Wegovy versus Eli Lilly's Zepbound is critical to gauge whether Novo Nordisk can stabilize its position.
• Given the stock's 46% year-to-date decline and the sharply lowered 2025 guidance, a significant amount of negative news may be priced in, but further downside is possible if the new, lower growth targets are not met.
• Evaluate the new CEO's strategy as a potential long-term turnaround play, but remain cautious as the company transitions from a hyper-growth phase to a more mature, competitive, and margin-focused operational model.